Veridien Climate Action ETF
Limited financial coverage for CLIA.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This fund aims to achieve its investment objectives by allocating capital to equity securities, including American Depositary Receipts (ADRs), issued by companies worldwide. It focuses on U. S.
- IPO
- 2023
- HQ
- US
Get TickerSpark's AI analysis on CLIA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $21.19
- 52W Low
- $16.48
- 50D MA
- $19.37
- 200D MA
- $19.18
- Beta
- 1.72
- RSI (14)
- 38
- Avg Volume
- 36.44K
No earnings-call transcripts are available for CLIA yet.
- Free Float
- 0.0%
- Shares Outstanding
- 1.36M
- Float Shares
- 0
Our CLIA coverage
Recent articles, reports, and earnings notes.
No research on CLIA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLIA report →bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
gurufocus.com · Oct 8
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
gurufocus.com · Oct 8
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
gurufocus.com · Oct 6
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
gurufocus.com · Sep 18
Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
businesswire.com · Aug 18
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
globenewswire.com · Jul 7
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
gurufocus.com · Jun 17
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual
gurufocus.com · May 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.